VLP-Based Vaccines as a Suitable Technology to Target Trypanosomatid Diseases
dc.contributor.author | Vasconcelos Queiroz, Aline Maria | |
dc.contributor.author | Wysllas de Freitas Oliveira, Johny | |
dc.contributor.author | Moreno, Cláudia Jassica | |
dc.contributor.author | Guerín Aguilar, Diego Marcelo A. ![]() | |
dc.contributor.author | Sousa Silva, Marcelo | |
dc.date.accessioned | 2021-04-13T14:44:25Z | |
dc.date.available | 2021-04-13T14:44:25Z | |
dc.date.issued | 2021-03-05 | |
dc.identifier.citation | Vaccines 9(3) : (2021) // Article ID 220 | es_ES |
dc.identifier.issn | 2076-393X | |
dc.identifier.uri | http://hdl.handle.net/10810/50903 | |
dc.description.abstract | Research on vaccines against trypanosomatids, a family of protozoa that cause neglected tropical diseases, such as Chagas disease, leishmaniasis, and sleeping sickness, is a current need. Today, according to modern vaccinology, virus-like particle (VLP) technology is involved in many vaccines, including those undergoing studies related to COVID-19. The potential use of VLPs as vaccine adjuvants opens an opportunity for the use of protozoan antigens for the development of vaccines against diseases caused by Trypanosoma cruzi, Leishmania spp., and Trypanosoma brucei. In this context, it is important to consider the evasion mechanisms of these protozoa in the host and the antigens involved in the mechanisms of the parasite–host interaction. Thus, the immunostimulatory properties of VLPs can be part of an important strategy for the development and evaluation of new vaccines. This work aims to highlight the potential of VLPs as vaccine adjuvants for the development of immunity in complex diseases, specifically in the context of tropical diseases caused by trypanosomatids. | es_ES |
dc.description.sponsorship | This research was funded by Global Health and Tropical Medicine (Grant number IHMT UID/multi/04413/2013 and Grant number PTDC/CVT-CVT/28908/2017), Fundação para Ciência e Tecnologia (FCT), Portugal; Grant GIU18/172 Grupos de Investigación de la UPV/EHU, and Grant from CSIC Programa I-COOP+2020 (ICOOPB20503), Spain. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | |
dc.subject | virus-like particles | es_ES |
dc.subject | vaccine | es_ES |
dc.subject | trypanosomatids | es_ES |
dc.subject | Chagas disease | es_ES |
dc.subject | leishmaniasis | es_ES |
dc.subject | African trypanosomiasis | es_ES |
dc.title | VLP-Based Vaccines as a Suitable Technology to Target Trypanosomatid Diseases | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.date.updated | 2021-03-26T14:08:23Z | |
dc.rights.holder | 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). | es_ES |
dc.relation.publisherversion | https://www.mdpi.com/2076-393X/9/3/220/htm | es_ES |
dc.identifier.doi | 10.3390/vaccines9030220 | |
dc.departamentoes | Bioquímica y biología molecular | |
dc.departamentoeu | Biokimika eta biologia molekularra |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).